VivoSeq
Oncology

Locally Advanced Urothelial Carcinoma

7

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Locally Advanced Urothelial Carcinoma is an early-stage landscape with 7 programs across 6 companies. The most active players are Avyxa, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Johnson & Johnson. 7 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avyxa

2 programs

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 3Teva logo

Teva

1 program

Phase 3Merck & Co. logo

Merck & Co.

1 program

Phase 3Gilead logo

Gilead

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

71%

Small molecule

5 of 7 classified programs — the dominant modality here.

29%ALL OTHERSMonoclonal antibody114%Antibody–drug conjugate114%

Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 100% of 7 pipeline programs.

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase III Randomized Trial of Pembrolizumab in Combination With Sacituzumab Govitean-hziy vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer
Recruiting·National Cancer Institute (NCI)·Phase 3·NCT06524544·320 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)